Windtree Therapeutics, Inc. (WINT) Regains Nasdaq Compliance

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") that Windtree has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. The Company will be subject to a mandatory panel monitor until March 20, 2026.

The Company was previously notified by Nasdaq on December 4, 2024 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive trading days, as required by the Nasdaq Listing Rules. To regain compliance with the rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. Nasdaq noted that this requirement was met and had been exhibited by a closing bid price of more than $1.00 since February 21, 2025.

You May Also Be Interested In

• Amer Sports Inc. (AS) PT Lowered to $42 at Truist, but 'Momentum continues to surge in a tough macro'
• Goldman Sachs Reiterates Buy Rating on Progressive Corp. (PGR)
• Benchmark Reiterates Hold Rating on Bio-Techne Corp. (TECH)